Scalp application of the antioxidant piroctone olamine reduces hair shedding in an 8-week randomized, double-blind, placebo-controlled clinical study

被引:3
|
作者
Davis, Michael G. [1 ]
Piliang, Melissa P. [2 ,3 ]
Bergfeld, Wilma F. [2 ,3 ]
Caterino, Tamara L. [1 ]
Fisher, Brian K. [1 ]
Sacha, Jarek P. [1 ]
Carr, Greg J. [1 ]
Moulton, Laura T. [1 ]
Whittenbarger, Deborah J. [1 ]
Punyani, Supriya [4 ]
Schwartz, James R. [1 ]
机构
[1] Procter & Gamble Co, Mason, OH 45040 USA
[2] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA
[4] Procter & Gamble Co, Singapore, Singapore
关键词
antioxidant; hair growth; hair loss; hair shedding; hair treatment; scalp; skin barrier; OXIDATIVE STRESS; SEBORRHEIC DERMATITIS; IRON; DANDRUFF;
D O I
10.1111/ics.12737
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Objective Increasing scalp hair fullness is a global unmet consumer need. An approach to decrease hair shedding by reducing scalp stratum corneum oxidation via a combination of antioxidant and barrier-enhancing technologies has been previously demonstrated. The purpose of this study was to test the effectiveness of the individual antioxidant piroctone olamine in two different product forms (shampoo or leave-on product) for activity to improve hair retention. Methods Female subjects with self-perceived hair thinning participated in an 8-week, double-blind, placebo-controlled, randomized clinical study to evaluate either a piroctone olamine (PO) containing shampoo or a PO containing leave on treatment, each relative to their corresponding placebo formulation Too many periods. Results for phototrichograms, TEWL, and biomarker analysis of scalp condition for the shampoo treatments are discussed. Phototrichogram results are shared for the assessment of the leave on treatment. Results Statistically significant increases in hair amount were observed by phototrichogram after use of both PO-containing products versus placebo formulations. The PO shampoo treatment also significantly decreased oxidative stress on the hair and scalp, and improved scalp condition as assessed by TEWL and scalp biomarker values. Conclusion These results illustrate the effectiveness of a cosmetic antioxidant to improve scalp condition thereby improving hair retention. The observed improvements in scalp condition are consistent with previous reports with other antioxidant technologies and suggest that the hair retention effect was achieved by preventing oxidative damage to the scalp.
引用
收藏
页码:S26 / S33
页数:8
相关论文
共 50 条
  • [11] An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    Lauriello, John
    Lambert, Tim
    Andersen, Scott
    Lin, Daniel
    Taylor, Cindy C.
    McDonnell, David
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (05) : 790 - 799
  • [12] Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial
    Chang, Jae Seung
    Ahn, Yong Min
    Park, Hye Jean
    Lee, Kyu Young
    Kim, Se Hyun
    Kang, Ung Gu
    Kim, Yong Sik
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (05) : 720 - 731
  • [13] A double-blind, placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis
    Vardy, DA
    Zvulunov, A
    Tchetov, T
    Biton, A
    Rosenman, D
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2000, 11 (02) : 73 - 77
  • [14] Olanzapine long-acting injection: An 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia
    Detke, H. C.
    McDonnell, D. P.
    Lauriello, J.
    Lambert, T.
    Andersen, S. W.
    Lin, D.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 152
  • [15] Efficacy and safety of ChondroT on knee-osteoarthritis Protocol for a 8-week, randomized, double-blind, placebo-controlled, multicenter therapeutic exploratory clinical trial
    Lee, Sangkwan
    Kim, Seon-Jong
    [J]. MEDICINE, 2018, 97 (12)
  • [16] Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
    Bidzan, Leszek
    Mahableshwarkar, Atul R.
    Jacobsen, Paula
    Yan, Mingjin
    Sheehan, David V.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (12) : 847 - 857
  • [17] Efficacy of Herbal Supplementation of Purslane Freeze-dried Juice for Weight Loss: An 8-week Randomized, Double-blind, Placebo-controlled Clinical Trial
    Tafti, Mehdi Ajdary
    Moein, Mahmoodreza
    Babajafari, Siavash
    Haem, Elham
    Zarshenas, Mohammad M.
    [J]. CURRENT TRADITIONAL MEDICINE, 2024, 10 (01) : 81 - 90
  • [18] Adjunctive tropisetron therapy for cognitive deficits in patients with schizophrenia: A 8-week, double-blind, placebo-controlled trial
    Shiina, A.
    Shirayama, Y.
    Niitsu, T.
    Hashimoto, T.
    Iyo, M.
    Hashimoto, K.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 241 - 241
  • [19] An 8-week, Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Ziprasidone in Patients with Major Depressive Disorder Receiving Treatment with Escitalopram
    Papakostas, George
    Swee, Michaela B.
    Baer, Lee
    Shelton, Richard C.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S344 - S345
  • [20] Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Lee, Young-Suk
    Lee, Kyu-Sung
    Choo, Myung-Soo
    Kim, Joon Chul
    Lee, Jeong Gu
    Seo, Ju Toe
    Lee, Jeong Zoo
    Lee, Ji Youl
    Oh, Seung-June
    Na, Yong Gil
    [J]. INTERNATIONAL NEUROUROLOGY JOURNAL, 2018, 22 (01) : 30 - 40